发布求助
文献互助 智能选刊 最新文献

Hellenic journal of nuclear medicine最新文献

筛选
英文 中文
The role of peptide receptor radionuclide therapy with Lu-177 Dotatate in metastatic gastroenteropancreaticneuroendocrine tumors. 肽受体放射性核素治疗与多酸铀-177在转移性胃肠胰神经内分泌肿瘤中的作用。
IF 0.8 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2026-01-01
Alexandros Georgakopoulos
{"title":"The role of peptide receptor radionuclide therapy with Lu-177 Dotatate in metastatic gastroenteropancreaticneuroendocrine tumors.","authors":"Alexandros Georgakopoulos","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Peptide Receptor Radionuclide Therapy (PRRT) has emerged as an established treatment modality for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), particularly in the second-line setting following progression on somatostatin analogs. Evidence from trials such as NETTER-1 and NETTER-2 has demonstrated significant improvements in progression-free survival and objective response rates, with expanding indications into first-line treatment and higher-grade disease. Emerging data from comparative and combination studies highlight the potential role of PRRT alongside targeted therapies and chemotherapy, although uncertainties remain regarding optimal sequencing and overall survival benefit. Retreatment strategies, special population considerations, and novel approaches including alpha-emitting radionuclides and somatostatin receptor antagonists further broaden the therapeutic landscape. Ongoing prospective trials are expected to refine patient selection and define the future role of PRRT across different tumor grades and clinical scenarios.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"29 Suppl ","pages":"29-35"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What changes in the therapeutic management of papillary thyroid carcinoma. Emerging evidence. 甲状腺乳头状癌治疗管理的变化。新兴的证据。
IF 0.8 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2026-01-01
Apostolos Goropoulos
{"title":"What changes in the therapeutic management of papillary thyroid carcinoma. Emerging evidence.","authors":"Apostolos Goropoulos","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The low mortality of papillary thyroid carcinoma (PTC) has led to progressively less aggressive therapeutic approaches according to the latest 2025 guidelines. However, morbidity associated with persistent disease and cervical lymph node metastases remains a significant clinical challenge. The presence of undetected \"occult\" metastases and the occurrence of nodal recurrences following apparently adequate treatment raise concerns regarding the effectiveness of current diagnostic and therapeutic strategies. Improving preoperative diagnostic accuracy in assessing both the extent and aggressiveness of the disease could play a decisive role in selecting the most appropriate surgical approach and the need for adjuvant radioactive iodine (RAI) therapy. Precise topographical localization of the tumor represents an additional risk factor that should be incorporated into therapeutic decision-making.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"29 Suppl ","pages":"36-42"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Choline positron emission tomography/computed tomography imaging in parathyroid neoplasms. 甲状旁腺肿瘤的胆碱正电子发射断层/计算机断层成像。
IF 0.8 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2026-01-01
Nikoletta K Pianou, Stylianos Gavriilidis, Anna Kiousi, Zisis Delichas, Athina Fothiadaki, Evangelia Vlontzou, Phoivi Rondogianni
{"title":"Choline positron emission tomography/computed tomography imaging in parathyroid neoplasms.","authors":"Nikoletta K Pianou, Stylianos Gavriilidis, Anna Kiousi, Zisis Delichas, Athina Fothiadaki, Evangelia Vlontzou, Phoivi Rondogianni","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Parathyroid glands are the smallest organs in our body,that regulate calcium metabolism, by producing parathyroid hormone (PTH). They are four, at least, as they might be either supernumerary or ectopic, especially in patients with chronic renal failure. Hyperparathyroidism (HPT) is a common endocrine disease, characterized by hormone imbalance, which leads to increased secretion of PTH. Primary hyperparathyroidism (PHPT) is caused by hyperfunctioning parathyroid glands, mainly by a solitary parathyroid adenoma and less frequently by parathyroid hyperplasia or double parathyroid adenomas. The alteration in calcium homeostasis, that stimulates the excessive production of PTH is called secondary HPT. Diagnosis of HPT may be clinical or incidental on biochemical screening. Surgical removal of hyperfunctioning parathyroid gland is the only curative treatment available at the moment. Minimally invasive parathyroidectomy (MIP) seems to be the surgical procedure of choice, as it demonstrates multiple advantages, such as reduced duration of surgery shorter hospitalization, with better cosmetic outcome and fewer patient complications. Preoperative imaging is therefore essential for those patients who are going to be treated surgically.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"29 Suppl ","pages":"70-74"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular imaging of TTR amyloidosis: New data. TTR淀粉样变的分子影像学：新资料。
IF 0.8 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2026-01-01
Paraskevi Exadaktylou, Kyriaki Papadopoulou, Vasileios Kamperidis, Ioannis Iakovou, Emmanouil Papanastasiou, Argiris Doumas
{"title":"Molecular imaging of TTR amyloidosis: New data.","authors":"Paraskevi Exadaktylou, Kyriaki Papadopoulou, Vasileios Kamperidis, Ioannis Iakovou, Emmanouil Papanastasiou, Argiris Doumas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Transthyretin cardiac amyloidosis (ATTR CM) is a recognized cause of heart failure that results from age related or hereditary transthyretin misfolding and systemic amyloid deposition. It is characterized by clinical heterogeneity and may affect the heart among peripheral and autonomous nervous system, gastrointestinal tract, kidneys and eyes. Technetium 99m bone avid scintigraphy with standardized planar and SPECT/CT protocols, interpreted using Perugini grading and heart to contralateral lung ratios after exclusion of light chain amyloidosis, enables highly sensitive, non invasive diagnosis of ATTR CM and early detection in at risk individuals. This narrative review synthesizes recent data on molecular imaging, emphasizing the central role of nuclear medicine physicians in applying multimodality diagnostic algorithms, recognizing typical and equivocal scan patterns. It further explores emerging roles for quantitative SPECT/CT and amyloid PET tracers in monitoring response to disease modifying therapies, including tetramer stabilizers (tafamidis, acoramidis), RNA interference silencers (vutrisiran, patisiran), and investigational fibril targeting antibodies and gene editing strategies, underscoring a shift from purely diagnostic imaging toward dynamic treatment monitoring in ATTR CM.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"29 Suppl ","pages":"140-149"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148967963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New radiopharmaceuticals in clinical applications, imaging and therapy -Updates in global situation New data. 临床应用、成像和治疗中的新放射性药物-全球形势的最新进展。
IF 0.8 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2026-01-01
Maria Papachristou
{"title":"New radiopharmaceuticals in clinical applications, imaging and therapy -Updates in global situation New data.","authors":"Maria Papachristou","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Traditional radiolabeling is insufficient foe the complies chemical space we are working with today. Efficient labeling of diverse heteroaromatic chemical space is where the radiochemical innovations begin. Rapid growth using nuclear medicine for personalized medicine and support drug discovery efforts, is putting unprecedented demand on radiochemistry manufacturing. New methods for rapid selection of a lead tracer, identification of labeling precursor and novel approaches for rapid radiosynthesis optimization, are required. Challenges with these new approaches: organic synthesis: making precursorsbecome a significant bottleneck, use-friendliness: requires a significant amount of focused work, adaptation and adoption: refine and generalize workflows, open-source, user friendly software tools, expansion: to other conditions, radionuclides andreaction manifolds.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"29 Suppl ","pages":"150-152"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148967984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nuclear Medicine through the patient's eyes: Diagnosis, Accuracy and Hope. 病人眼中的核医学：诊断、准确性和希望。
IF 0.8 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2026-01-01
Kaiti Kontopoulou
{"title":"Nuclear Medicine through the patient's eyes: Diagnosis, Accuracy and Hope.","authors":"Kaiti Kontopoulou","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>For scientists, Nuclear Medicine is a dynamic and evolving branch of medical science, with high-tech tools, highly precise imaging methods, and therapeutic applications that open up new doors and opportunities. As for the patient, Nuclear Medicine is much more. It is the moment when science meets anxiety, uncertainty, but nonetheless hope.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"29 Suppl ","pages":"109-110"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular risk assessment in oncologic patients. A narrative review. 肿瘤患者的心血管风险评估。叙述性评论
IF 0.8 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2026-01-01
Christos T Lafaras, Kyranna C Lafara, Evdokia M Mandala
{"title":"Cardiovascular risk assessment in oncologic patients. A narrative review.","authors":"Christos T Lafaras, Kyranna C Lafara, Evdokia M Mandala","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Systematic cardiovascular risk assessment and stratification across the entire cancer care continuum is essential among cancer patients, largely due to potential cardiotoxic effects of oncologic therapeutic regiments. Prior to initiation of cancer therapy, cardiotoxicity risk assessment should include comprehensive evaluation of baseline cardiovascular status and baseline measurement of cardiac biomarkers. Patient-related factors should be integrated with therapy-related risks associated with specific oncologic regiments and/or radiotherapy. During cancer treatment, continuous cardiovascular surveillance is necessary to detect early or subclinical myocardial dysfunction. Monitoring strategies involve periodic clinical evaluation, serial echocardiographic assessment and biomarker measurements. Surveillance protocols should be adapted according to the cardiotoxic potential of the administered regimen; as early detection of cardiotoxicity allows prompt cardioprotective interventions and adjustment of oncologic treatments. Cardiovascular assessment after cancer therapy is crucial due to potential delayed cardiotoxic effects. During the first year, post-treatment, structured follow-up is recommended to identify persistent or emerging cancer therapy-related cardiotoxicities. Long-term surveillance is also particularly important for cancer survivors exposed to cardiotoxic agents, given their increased risk of chronic cardiovascular complications. Digitalization improves cardio-oncology risk assessment through artificial intelligence, electronic health records, and remote monitoring enabling earlier detection and personalized cardiovascular surveillance. A multidisciplinary cardio-oncology approach and structured surveillance across the entire cancer care continuum is crucial to reduce cardiovascular morbidity and improve long-term outcomes.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"29 Suppl ","pages":"43-52"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The brain and nous in Greek antiquity. 古代希腊人的大脑和鼻子。
IF 1 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2026-01-01 Epub Date: 2026-04-20 DOI: 10.1967/s002449912950
Spyros Retsas
{"title":"The brain and nous in Greek antiquity.","authors":"Spyros Retsas","doi":"10.1967/s002449912950","DOIUrl":"10.1967/s002449912950","url":null,"abstract":"","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"54-57"},"PeriodicalIF":1.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rhenium-188 in the treatment of non-melanoma skin cancer. 铼-188在治疗非黑色素瘤皮肤癌中的作用。
IF 0.8 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2026-01-01
A Charoupa
{"title":"Rhenium-188 in the treatment of non-melanoma skin cancer.","authors":"A Charoupa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Non-melanoma skin cancer (NMSC) is one of the most frequently diagnosed malignancies worldwide, especially among fair-skinned individuals. Basal cell carcinoma (BCC) is the predominant subtype, whereas squamous cell carcinoma (SCC) accounts for a smaller but increasing proportion of cases. The incidence of these tumors continues to rise due to aging populations, cumulative ultraviolet exposure and improved detection. Lesions are commonly located on cosmetically sensitive regions such as the face, scalp and neck, where treatment may significantly affect both function and appearance. Conventional therapeutic approaches include surgery, radiotherapy, cryotherapy and topical agents; however, these treatments may be associated with recurrence, cosmetic impairment or prolonged treatment duration. Rhenium-188 skin cancer therapy is a topical radionuclide-based treatment designed for superficial lesions. Owing to the limited tissue penetration of beta radiation, it can deliver high doses to the lesion while preserving surrounding healthy tissues. Published clinical evidence suggests high local control rates, good cosmetic outcomes and acceptable toxicity profiles. Therefore, Rhenium-188 may represent a valuable alternative for carefully selected patients with superficial NMSC.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"29 Suppl ","pages":"5-9"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The experience of Nuclear Medicine Department of G.N.A. Evangelismos on the therapy with 177Lu-PSMA. 福音医院核医学科应用177Lu-PSMA治疗的体会。
IF 0.8 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2026-01-01
Athina Fothiadaki, Evangelia Vlotzou, Theodoros Tegos, Maria Papachristou, Nikolaos Bertsekas, Aikaterine Grigorakou, Spiridoula Kalentziou, Foivi Rontogianni
{"title":"The experience of Nuclear Medicine Department of G.N.A. Evangelismos on the therapy with <sup>177</sup>Lu-PSMA.","authors":"Athina Fothiadaki, Evangelia Vlotzou, Theodoros Tegos, Maria Papachristou, Nikolaos Bertsekas, Aikaterine Grigorakou, Spiridoula Kalentziou, Foivi Rontogianni","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of the presented study was to evaluate the efficacy and safety of <sup>177</sup>Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) in a hospital clinical setting.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"29 Suppl ","pages":"10-12"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书